Early use of mycophenolate mofetil (MMF), a drug used to dampen the immune system in organ transplant recipients, may reduce the risk for severe flares in patients with newly diagnosed systemic lupus ...

Please provide your email address to receive an email when new articles are posted on . MMF demonstrated comparable safety and greater reductions in AST and ALT vs. azathioprine in autoimmune ...

Ex-movie theater projectionist Steve Guttenberg has also worked as a high-end audio salesman, and as a record producer. Steve reviewed audio products for CNET and worked as a freelance writer for ...

Belimumab showed efficacy in a subgroup of patients with lupus nephritis treated with MMF as standard of care background therapy. Belimumab reduces proteinuria in patients with class 3 or 4 lupus ...

Patients with dermatologic conditions showed a 74% lower risk for malignancy with mycophenolate mofetil (MMF) than transplant patients, a study found. Researchers conducted a single-center ...

Among patients with systemic lupus erythematosus (SLE) managed successfully with mycophenolate mofetil (MMF), rates of disease flare were not massively greater when the drug was withdrawn over several ...

Mycophenolate mofetil is associated with comparable treatment outcomes to methotrexate among patients with juvenile localized ...

Data from a randomized controlled trial show that mycophenolate mofetil (MMF) did not significantly reduce proteinuria in patients with IgA nephropathy (IgAN) who had failed to respond to initial ...